Abstract
Hereditary angioedema (HAE) is characterized by acute attacks of edema with multiple localizations, the laryngeal angioedema being the most potentially lethal. In HAE, C1-INH impairments cause episodic increase in kallikrein activity leading to attacks of angioedema. Several therapies have recently become available to treat or to prevent HAE attacks, and others are under evaluation for this indication. Plasma-derived C1-INH, bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or recombinant C1-INH is authorized on the market for HAE attack therapy or prophylaxis. Some of these compounds can be used exclusively to treat HAE attacks, whereas others can also be used as prophylactic therapies. Such therapies, although not available worldwide, can improve disease outcome due to their different mechanisms of action.
Similar content being viewed by others
References
Bowen T, Cicardi M, Farkas H et al (2010) International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6(1):24
Zuraw BL HAE therapies: past present and future. Allergy Asthma Clin Immunol 6(1):23
Kaplan AP Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. J Allergy Clin Immunol
Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 15(2):69–78
Craig T, Riedl M, MS Dykewicz et al (2009) When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 102(5):366–372
AE Davis (2005) 3RD: the pathophysiology of hereditary angioedema. Clin Immunol 114(1):3–9
Quastel M, Harrison R, Cicardi M, CA Alper, FS Rosen (1983) Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 71(4):1041–1046
Cugno M, Nuijens J, Hack E et al (1990) Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 85(4):1215–1220
Pappalardo E, LC Zingale, Terlizzi A et al (2002) Mechanisms of C1-inhibitor deficiency. Immunobiology 205(4–5):542–551
Pappalardo E, LC Zingale, Cicardi M (2004) C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J Allergy Clin Immunol 114(3):638–644
ED Han, RC Macfarlane, AN Mulligan, Scafidi J, AE Davis (2002) 3RD: increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109(8):1057–1063
AP Kaplan, Joseph K, Silverberg M (2002) Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109(2):195–209
Joseph K, BG Tholanikunnel, AP Kaplan (2002) Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 99(2):896–900
KD Bhoola, CD Figueroa, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44(1):1–80
Marcondes S, Antunes E (2005) The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr Med Chem Cardiovasc Hematol Agents 3(1):33–44
Longhurst HJ Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag 6:795–802
Cugno M, Nussberger J, Cicardi M, Agostoni A (2003) Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 3(3):311–317
Nussberger J, Cugno M, Amstutz C et al (1998) Plasma bradykinin in angio-oedema. Lancet 351(9117):1693–1697
Cugno M, Cicardi M, Bottasso B et al (1997) Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89(9):3213–3218
FJ Hock, Wirth K, Albus U et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102(3):769–773
Wirth K, FJ Hock, Albus U et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102(3):774–777
JR Cockcroft, PJ Chowienczyk, SE Brett, Bender N, JM Ritter (1994) Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 38(4):317–321
http://www.ema.europa.euFirazyr: EPAR-product information (2008)
Bork K, Frank J, Grundt B et al (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119(6):1497–1503
Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532–541
JA Bernstein (2008) Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol 100(1 Suppl 2):S41–S46
Bernstein JA, Qazi M Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 6(1):29–39
Schneider L, Lumry W, Vegh A, AH Williams, Schmalbach T (2007) Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120(2):416–422
Cicardi M, Levy RJ, Mcneil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363(6):523–531
Levy RJ, Lumry WR, Mcneil DL et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104(6):523–529
Davis AE, 3RD, Lu F, Mejia P C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104(5)
C1 esterase inhibitor (human) P T 35(7 Section 2):2–3
ED Hanlee, Pappalardo E, Scafidi J, AE Davis (2003) 3RD: approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett 89(2–3):155–160
TJ Craig, RJ Levy, RL Wasserman et al (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124(4):801–808
Bernstein JA, Ritchie B, LEVY RJ et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 105(2):149–154
Craig TJ, Wasserman RL, Levy RJ et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol
Cocchio C, Marzella N (2009) Cinryze, a human plasma-derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. P T 34(6):293–328
Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363(6):513–522
Eldering E, JH Nuijens, CE Hack (1988) Expression of functional human C1 inhibitor in COS cells. J Biol Chem 263(24):11776–11779
Lamark T, Ingebrigtsen M, Bjornstad C et al (2001) Expression of active human C1 inhibitor serpin domain in escherichia coli. Protein Expr Purif 22(2):349–358
van Doorn MB, Burggraaf J, van Dam T et al (2005) A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 116(4):876–883
Choi G, MR Soeters, Farkas H et al (2007) Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47(6):1028–1032
Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126(4):821–827 e814
http://www.ema.europa.euCommittee for medicinal products for human use positive summary of opinion for ruconest (2010)
IG Bos, EC Debruin, YA Karuntu et al (2003) Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor. Biochim Biophys Acta 1648(1–2):75–83
Agostoni A, Aygoren-Pursun E, KE Binkley et al (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114(3 Suppl):S51–S131
MC Owen, SO Brennan, JH Lewis, RW Carrell (1983) Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 309(12):694–698
Schapira M, MA Ramus, Jallat S, Carvallo D, Courtney M (1986) Recombinant alpha 1-antitrypsin Pittsburgh (Met 358––Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. J Clin Invest 77(2):635–637
PA Patston, Roodi N, JA Schifferli et al (1990) Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems. J Biol Chem 265(18):10786–10791
Sulikowski T, BA Bauer, PA Patston (2002) Alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1. Protein Sci 11(9):2230–2236
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Antoniu, S.A. Therapeutic Approaches in Hereditary Angioedema. Clinic Rev Allerg Immunol 41, 114–122 (2011). https://doi.org/10.1007/s12016-011-8254-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-011-8254-2